Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Assets Average: 2009-2025

Historic Assets Average for Cytokinetics (CYTK) over the last 15 years, with Sep 2025 value amounting to $1.3 billion.

  • Cytokinetics' Assets Average fell 10.06% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 10.06%. This contributed to the annual value of $1.1 billion for FY2024, which is 21.04% up from last year.
  • Latest data reveals that Cytokinetics reported Assets Average of $1.3 billion as of Q3 2025, which was up 6.93% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Assets Average ranged from a high of $1.5 billion in Q3 2024 and a low of $555.4 million during Q1 2021.
  • Moreover, its 3-year median value for Assets Average was $1.2 billion (2024), whereas its average is $1.1 billion.
  • Its Assets Average has fluctuated over the past 5 years, first soared by 133.37% in 2021, then decreased by 25.15% in 2023.
  • Over the past 5 years, Cytokinetics' Assets Average (Quarterly) stood at $834.4 million in 2021, then grew by 25.28% to $1.0 billion in 2022, then dropped by 25.15% to $782.5 million in 2023, then soared by 81.33% to $1.4 billion in 2024, then fell by 10.06% to $1.3 billion in 2025.
  • Its Assets Average stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.